Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis

BACKGROUND: Real‐world evidence of second‐line treatment and beyond with immune checkpoint inhibitors (ICIs) in Chinese patients is lacking. Here, we aimed to assess the efficacy, responses, and immune‐related side effects of anti‐PD‐1 agents in real‐life practice. METHODS: We retrospectively analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Minjiang, Li, Qiang, Xu, Yan, Zhao, Jing, Zhang, Li, Wei, Lijuan, Zhong, Wei, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327684/
https://www.ncbi.nlm.nih.gov/pubmed/32468726
http://dx.doi.org/10.1111/1759-7714.13488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327684/
https://www.ncbi.nlm.nih.gov/pubmed/32468726
http://dx.doi.org/10.1111/1759-7714.13488

Ejemplares similares